Alec's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2024
Question
Alec asked how the combined company plans to leverage Exscientia's automated laboratories.
Answer
CEO Christopher Gibson stated that Exscientia's state-of-the-art automated synthesis platform, which integrates active learning, is a capability Recursion has not built and will be critical for driving programs with challenging chemistry more efficiently. David Hallett, Interim CEO of Exscientia, added that the closed-loop system could generate experimental data to validate and improve predictive models from other parts of the business, such as Cyclica's MatchMaker tool.